Endocrine Abstracts

Introduction: TKI are an emerging group of anti-growth factor agents used in the treatment of solid cancers. Treatment is associated with thyroid dysfunction. Sunitinib is licensed for the treatment of metastatic RCC. Our objective was to determine the incidence of Sunitinib induced thyroid dysfunction and its management in patients with renal RCC.Methods: Retrospective case note analysis of patients started on Sunitinib for metastatic RCC between Januar...